...
机译:单独进行中的替米沙坦的心脏MRI研究与雷米普利全球终点试验/替米沙坦的随机评估研究相结合,用于ACE耐受性心血管疾病患者:分析方案和基线特征
Auckland MRI Research Group, University of Auckland, Auckland, New Zealand;
Auckland MRI Research Group, University of Auckland, Auckland, New Zealand;
Clinical Trials Research Unit, School of Population Health, University of Auckland, Auckland, New Zealand;
Department of Medicine, University of Auckland, Auckland, New Zealand;
Division of Cardiology, Department of Medicine, Siriraj Hospital, Bangkok, Thailand;
Department of Medicine, Division of Cardiology and Population Health Research Institute, McMaster University, Hamilton, ON, Canada;
Department of Medicine, University of Queensland, Brisbane, Australia;
Auckland MRI Research Group, University of Auckland, Auckland, New Zealand;
Department of Cardiovascular Medicine, University of Birmingham, Birmingham, UK;
Department of Nephrology and Hypertension, Friedrich-Alexander-University, Erlangen-Nürnberg, Germany;
Department of Medicine, Division of Cardiology and Population Health Research Institute, McMaster University, Hamilton, ON, Canada;
Clinical Trials Research Unit, School of Population Health, University of Auckland, Auckland, New Zealand;
Auckland MRI Research Group, University of Auckland, Auckland, New Zealand;
Auckland MRI Research Group, University of Auckland, Auckland, New Zealand;
Department of Medicine, Division of Cardiology and Population Health Research Institute, McMaster University, Hamilton, ON, Canada;
Auckland MRI Research Group, University of Auckland, Auckland, New Zealand;
Cardiac MRI; ONTARGET; TRANSCEND; Trials; Left ventricular dysfunction; Telmisartan; Ramipril;
机译:心血管高危患者的性功能,满意度以及勃起功能障碍与心血管疾病和危险因素的关联:正在进行中的替米沙坦单独研究以及与雷米普利全球终点试验/替米沙坦的随机评估研究相结合,用于ACE耐受的心血管疾病患者(目标/超越)
机译:性别对高心血管风险患者的心血管结局的影响:替米沙坦随机评估研究在ACE不耐受的心血管疾病患者中进行(TRANSCEND),以及正在进行的替米沙坦单独治疗和雷米普利全球终点试验(ONTARGET)的分析
机译:勃起功能障碍可预测接受替米沙坦,雷米普利或同时接受这两种药物的高危患者的心血管事件:正在进行中的替米沙坦单独治疗以及与雷米普利全球终点试验/替米沙坦的随机评估一起在ACE耐受性心血管疾病受试者中进行(ONTARGET / TRANSCEND)
机译:替米沙坦联合雷米普利和氯沙坦联合雷米普利口服固定剂量治疗高血压的成年印度裔患者的多中心前瞻性随机双盲III期试验
机译:性别对高心血管风险患者心血管结局的影响分析:替米沙坦随机评估研究的ACE耐受性心血管疾病患者(TRANSCEND)和持续进行的替米沙坦单独治疗,以及联合雷米普利全球终点试验(ONTARGET)